Herbert “Skip” Virgin is joining Vir Biotechnology to become executive vice president of research and chief scientific officer of the San Francisco-based drug developer. Virgin, who will start his new post on Jan. 1, comes to Vir from Washington University’s School of Medicine, where he has been a professor and chair of the department of pathology and immunology since 2006. Earlier this year, Vir revealed $500 million in committed funding that the startup will use to develop new infectious disease treatments.
